Kang Seung-Gul, Lee Heon-Jeong, Park Young-Min, Choi Jung-Eun, Han Changsu, Kim Yong-Ku, Kim Seung-Hyun, Lee Min-Soo, Joe Sook-Haeng, Jung In-Kwa, Kim Leen
Department of Psychiatry, Korea University College of Medicine, Seoul, South Korea.
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):160-3. doi: 10.1016/j.pnpbp.2007.08.002. Epub 2007 Aug 14.
Antipsychotic-induced weight gain has important effects on treatment compliance and long-term health. Several reports have indicated that a -2548A/G single-nucleotide polymorphism (SNP) of the leptin gene is associated with antipsychotic-induced weight gain. We hypothesized that there is a similar relationship between the -2548A/G SNP and olanzapine-induced weight gain. A total of 74 Korean schizophrenic patients were examined. Their weight was measured before starting olanzapine and after long-term treatment lasting for at least 3 months. The weight gain was significantly higher for patients with the AG genotype than for those with the AA genotype (p=0.029). Analysis of covariance also showed the difference of weight gain was still significant when adjusted for sex and treatment duration (p=0.046). This finding supports the presence of a relationship between the -2548A/G SNP of the leptin gene and weight gain in Korean schizophrenic patients receiving olanzapine treatment.
抗精神病药物所致体重增加对治疗依从性和长期健康有重要影响。多项报告表明，瘦素基因的-2548A/G单核苷酸多态性（SNP）与抗精神病药物所致体重增加有关。我们推测，-2548A/G SNP与奥氮平所致体重增加之间存在类似关系。共对74名韩国精神分裂症患者进行了检查。在开始使用奥氮平之前以及至少持续3个月的长期治疗之后测量他们的体重。AG基因型患者的体重增加显著高于AA基因型患者（p=0.029）。协方差分析还显示，在对性别和治疗持续时间进行校正后，体重增加的差异仍然显著（p=0.046）。这一发现支持了在接受奥氮平治疗的韩国精神分裂症患者中，瘦素基因的-2548A/G SNP与体重增加之间存在关联。
